RekrutujeFaza III
Badanie fazy III leku AZD0120 i daratumumab
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Badane leki: AZD0120daratumumabdexamethasoneisatuximab
+7
+7Szpiczak: badania kliniczne, Gdańsk
Badania kliniczne w obszarze: szpiczak, prowadzone w ośrodkach w mieście Gdańsk. Zobacz też wszystkie badania: szpiczak w Polsce.
25 badań: 21 rekrutuje, 4 wkrótce zaczną.
Lista badań
RekrutujeFaza III
Badanie fazy III leku bortezomib i lenalidomide
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in…
Badane leki: bortezomiblenalidomidedaratumumabdexamethasone
+10
+10RekrutujeFaza III
Badanie fazy III leku pomalidomide i elotuzumab
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Badane leki: pomalidomideelotuzumabdexamethasonecarfilzomib+10
+10RekrutujeFaza III
Badanie fazy III leku teclistamab
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Badane leki: teclistamab+10
+10RekrutujeFaza III
Badanie fazy III leku dexamethasone i pomalidomide
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple…
Badane leki: dexamethasonepomalidomidecarfilzomibAZD0120+7
+7RekrutujeFaza III
Badanie fazy III leku linvoseltamab i daratumumab
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Badane leki: linvoseltamabdaratumumab
+6
+6RekrutujeFaza II
Badanie fazy II leku cemsidomide i dexamethasone
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Badane leki: cemsidomidedexamethasone
Rekrutuje
Badanie kliniczne
Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
Badane leki: apixabanrivaroxabanneoparin
RekrutujeFaza III
Badanie fazy III leku dexamethasone i dexamethasone phosphate
An Open-label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab plus Carfilzomib versus Standard of Care Combination Regimens in Patients with…
Badane leki: dexamethasonedexamethasone phosphatecarfilzomibpomalidomide
+13
+13RekrutujeFaza III
Badanie fazy III leku teclistamab i TAK-339
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Badane leki: teclistamabTAK-339+9
+9RekrutujeFaza III
Badanie fazy III leku pomalidomide i cyclophosphamide
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma…
Badane leki: pomalidomidecyclophosphamidedexamethasonetocilizumab
+23
+23RekrutujeFaza II
Badanie fazy II leku diphenhydramine hydrochloride i dexamethasone phosphate
PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE…
Badane leki: diphenhydramine hydrochloridedexamethasone phosphatelinvoseltamabtocilizumab
RekrutujeFaza III
Badanie fazy III leku lenalidomide i enoxaparin sodium
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Badane leki: lenalidomideenoxaparin sodiumrivaroxabaniberdomide+27
+27RekrutujeFaza III
Badanie fazy III leku dexamethasone phosphate i pomalidomide
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple…
Badane leki: dexamethasone phosphatepomalidomidelinvoseltamabelotuzumab
+10
+10RekrutujeFaza I/II
Badanie fazy I/II leku belantamab i belantamab mafodotin
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Badane leki: belantamabbelantamab mafodotinpomalidomidedexamethasone
+11
+11RekrutujeFaza III
Badanie fazy III leku lenalidomide i dexamethasone
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in…
Badane leki: lenalidomidedexamethasonebortezomibdaratumumab+21
+21RekrutujeFaza I/II
Badanie fazy I/II leku iberdomide i cevostamab
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Badane leki: iberdomidecevostamablenalidomidetocilizumab
RekrutujeFaza III
Badanie fazy III leku lenalidomide i teclistamab
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance…
Badane leki: lenalidomideteclistamab+17
+17RekrutujeFaza III
Badanie fazy III leku pomalidomide i dexamethasone
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Badane leki: pomalidomidedexamethasoneelranatamabdaratumumab+18
+18RekrutujeFaza I
Badanie fazy I leku cevostamab i tocilizumab
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Badane leki: cevostamabtocilizumabpomalidomidedaratumumab+6
+6RekrutujeFaza II
Badanie fazy II leku talquetamab
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Badane leki: talquetamab+3
+3Rekrutacja wkrótceFaza III
Badanie fazy III leku bortezomib i lenalidomide
A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR…
Badane leki: bortezomiblenalidomideisatuximabAZD0120+8
+8Rekrutacja wkrótceFaza II
Badanie fazy II leku dapagliflozin
A Randomized, Double-Blind, Phase 2 Trial Evaluating the Efficacy, Safety and Tolerability of Primary Cardioprotection with Dapagliflozin in Patients with Newly Diagnosed…
Badane leki: dapagliflozin
Rekrutacja wkrótceFaza III
Badanie fazy III leku AZD0120 i cyclophosphamide
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant…
Badane leki: AZD0120cyclophosphamidefludarabinelenalidomide+7
+7Rekrutacja wkrótceFaza II
Badanie fazy II leku pomalidomide i belantamab mafodotin
Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.
Badane leki: pomalidomidebelantamab mafodotindexamethasone
Szpiczak: inne miasta
Nie wiesz, które badanie jest dla Ciebie?
Zadzwoń i porozmawiaj z doradcą ds. badań klinicznych. Sprawdzimy w rejestrach, do których badań możesz się kwalifikować.
Zadzwoń do naszego specjalisty+48 664 930 800pon-pt: 9:00 - 18:00
Wolisz, żebyśmy oddzwonili? Zostaw numer
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 2 października 2026.